Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Beta-crystallin B2 (CRYBB2)
- Target
- CRYBB2
- Molecular classification
- Structural protein, Beta-crystallin family, Beta/gamma-crystallin superfamily
01
Overview
Beta-crystallin B2 (CRYBB2) is a structural protein encoded by the CRYBB2 gene, predominantly found in the vertebrate eye lens. As a member of the beta-crystallin family, it plays a critical role in maintaining lens transparency and refractive index by forming stable oligomeric complexes with other crystallins. Beta-crystallin B2 is highly expressed and retained throughout the lifetime of lens cells, contributing to their extreme stability. Mutations in CRYBB2 can lead to various congenital cataract phenotypes and are also linked, in animal models, to neurodevelopmental alterations. There is no evidence of direct therapeutic targeting or druggability of this protein; its clinical relevance is confined primarily to genetics and structural biology of the eye lens.
- Other names
- CRYBB2CRYB2CRYB2ABeta-B2 crystallinBeta-crystallin BpCCA2CTRCT3D22S665CTA-221G9.7Eye lens structural proteinbeta-crystallin B2
02
Biological functions
Structural support in the vertebrate eye lensMaintenance of lens transparency and refractive indexFormation and stabilization of high-order protein networks in the lensHomodimerization and heterodimerization with other crystallinsMaintenance of protein solubility and prevention of aggregationMay have roles in the central nervous system, e.g., antisaccade performance, dendritogenesis, axonal regeneration
03
Disease associations
Congenital cataract (e.g., cerulean cataract, central nuclear, polymorphic cataracts)Potential link to neuropsychiatric phenotypes (such as schizophrenia endophenotypes in animal models; however, not confirmed as causal in humans)Microphthalmia
04
Safety considerations
Not a drug target, so specific therapeutic safety concerns do not applyMutations cause inherited cataracts, but no safety concerns related to therapeutic intervention
05
Biomarkers
Mutations in CRYBB2 are genetic markers for inherited forms of cataractPost-translational modifications, such as deamidation, are linked to lens aging and cataract pathology
Beyond the preview
Go deeper on Beta-crystallin B2 (CRYBB2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Beta-crystallin B2 (CRYBB2).